These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 22123703)

  • 1. Changes in the use of broad-spectrum antibiotics after cefepime shortage: a time series analysis.
    Plüss-Suard C; Pannatier A; Ruffieux C; Kronenberg A; Mühlemann K; Zanetti G
    Antimicrob Agents Chemother; 2012 Feb; 56(2):989-94. PubMed ID: 22123703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of a nationwide antibiotic restriction program on antibiotic usage and resistance against nosocomial pathogens in Turkey.
    Altunsoy A; Aypak C; Azap A; Ergönül Ö; Balık I
    Int J Med Sci; 2011; 8(4):339-44. PubMed ID: 21647326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams.
    Paul M; Yahav D; Bivas A; Fraser A; Leibovici L
    Cochrane Database Syst Rev; 2010 Nov; 2010(11):CD005197. PubMed ID: 21069685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.
    Taccone FS; Laterre PF; Dugernier T; Spapen H; Delattre I; Wittebole X; De Backer D; Layeux B; Wallemacq P; Vincent JL; Jacobs F
    Crit Care; 2010; 14(4):R126. PubMed ID: 20594297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
    Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
    J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective evaluation of piperacillin-tazobactam, imipenem-cilastatin and meropenem used on surgical floors at a tertiary care hospital in Saudi Arabia.
    Youssif E; Aseeri M; Khoshhal S
    J Infect Public Health; 2018; 11(4):486-490. PubMed ID: 29153444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
    Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
    Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefepime restriction improves gram-negative overall resistance patterns in neonatal intensive care unit.
    de Araujo OR; da Silva DC; Diegues AR; Arkader R; Cabral EA; Afonso MR; Louzada ME; Albertoni Ade C
    Braz J Infect Dis; 2007 Apr; 11(2):277-80. PubMed ID: 17625777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy.
    Seyler L; Cotton F; Taccone FS; De Backer D; Macours P; Vincent JL; Jacobs F
    Crit Care; 2011; 15(3):R137. PubMed ID: 21649882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective drug utilization evaluation of three broad-spectrum antimicrobials: cefepime, piperacillin-tazobactam and meropenem.
    Raveh D; Muallem-Zilcha E; Greenberg A; Wiener-Well Y; Schlesinger Y; Yinnon AM
    QJM; 2006 Jun; 99(6):397-406. PubMed ID: 16682440
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Goodlet KJ; Nicolau DP; Nailor MD
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of computerized pre-authorization of broad spectrum antibiotics in Pseudomonas aeruginosa at a children's hospital in Japan.
    Horikoshi Y; Higuchi H; Suwa J; Isogai M; Shoji T; Ito K
    J Infect Chemother; 2016 Aug; 22(8):532-5. PubMed ID: 27263807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
    Sun HK; Kuti JL; Nicolau DP
    Crit Care Med; 2005 Oct; 33(10):2222-7. PubMed ID: 16215374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
    Erdem I; Kucukercan M; Ceran N
    Chemotherapy; 2003 Dec; 49(6):294-7. PubMed ID: 14671429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial resistance patterns of Pseudomonas aeruginosa in tertiary care hospitals of Makkah and Jeddah.
    Khan MA; Faiz A
    Ann Saudi Med; 2016; 36(1):23-8. PubMed ID: 26922684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosa.
    Pankuch GA; Lin G; Kubo A; Armstrong ES; Appelbaum PC; Kosowska-Shick K
    Antimicrob Agents Chemother; 2011 May; 55(5):2463-5. PubMed ID: 21282445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
    Harris PNA; Tambyah PA; Lye DC; Mo Y; Lee TH; Yilmaz M; Alenazi TH; Arabi Y; Falcone M; Bassetti M; Righi E; Rogers BA; Kanj S; Bhally H; Iredell J; Mendelson M; Boyles TH; Looke D; Miyakis S; Walls G; Al Khamis M; Zikri A; Crowe A; Ingram P; Daneman N; Griffin P; Athan E; Lorenc P; Baker P; Roberts L; Beatson SA; Peleg AY; Harris-Brown T; Paterson DL;
    JAMA; 2018 Sep; 320(10):984-994. PubMed ID: 30208454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AmpG inactivation restores susceptibility of pan-beta-lactam-resistant Pseudomonas aeruginosa clinical strains.
    Zamorano L; Reeve TM; Juan C; Moyá B; Cabot G; Vocadlo DJ; Mark BL; Oliver A
    Antimicrob Agents Chemother; 2011 May; 55(5):1990-6. PubMed ID: 21357303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of piperacillin-tazobactam shortage on meropenem use: implications for antimicrobial stewardship programs.
    Barber KE; Bell AM; Travis King S; Parham JJ; Stover KR
    Braz J Infect Dis; 2016; 20(6):631-634. PubMed ID: 27609214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotic rotation for febrile neutropenic patients with hematological malignancies: clinical significance of antibiotic heterogeneity.
    Chong Y; Shimoda S; Yakushiji H; Ito Y; Miyamoto T; Kamimura T; Shimono N; Akashi K
    PLoS One; 2013; 8(1):e54190. PubMed ID: 23372683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.